Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Levilactobacillus brevis KABP-052 + Lactiplantibacillus plantarum KABP-051 + Pediococcus acidilactici KABP-021
- Development stage
- Unknown
- Lead developer
- AB-BIOTICS
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Levilactobacillus brevis KABP-052 + Lactiplantibacillus plantarum KABP-051 + Pediococcus acidilactici KABP-021 is a probiotic combination developed by AB-Biotics (a company of the Kaneka Group) and marketed under the brand name Gyntima Menopause. This formulation consists of three live bacterial strains in a 2:1:1 ratio. The combination works by modulating the estrabolome (gut bacteria that metabolize estrogen) through beta-glucuronidase (GUS) enzyme activity, which increases estrogen deconjugation and helps sustain estrogen levels in the body. It is indicated for managing menopause symptoms in peri- and post-menopausal women. The lead strain, Levilactobacillus brevis KABP-052, was selected for its high capacity to deconjugate estrogen, while the other two strains were chosen for their ability to inhibit opportunistic pathogens and improve gut homeostasis. Clinical studies have shown that after 12 weeks of supplementation, the blend sustained estrogen levels compared to placebo in women aged 45-55. These same strains have also been studied for oral health applications, including gingivitis treatment and reduction of dental plaque.
- Brand names
- Gyntima MenopauseAB-Dental
- Other names
- AB-Biotics Menopause BlendGyntima Menopause probiotic
02
Targets
GUSB (Beta-glucuronidase)
Beyond the preview
Go deeper on Levilactobacillus brevis KABP-052 + Lactiplantibacillus plantarum KABP-051 + Pediococcus acidilactici KABP-021.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Levilactobacillus brevis KABP-052 + Lactiplantibacillus plantarum KABP-051 + Pediococcus acidilactici KABP-021.